Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2022-08-01
|
| Saila: | Medicina |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.mdpi.com/1648-9144/58/9/1180 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|